Company Performance Metrics
RASGenix develops biotechnology services focused on preclinical oncology research as a specialized contract research organization. The company concentrates on RAS-dependent diseases and uses its expertise in the RAS gene family to support drug discovery efforts. It provides customized RAS mutation cell line platforms that allow clients to screen
anti-tumor compounds in controlled cellular environments. RasGenix also offers complex custom genetic manipulation models designed to capture disease heterogeneity and enable detailed evaluation of molecular targets. These capabilities are delivered through structured preclinical screening packages tailored for pharmaceutical companies, academic laboratories, and biotech firms. The services help research teams compare therapeutic strategies against specific RAS mutations in a preclinical setting and refine their development pipelines.
